Scott Kopetz, MD – KRYSTAL-1: Adagrasib-Cetuximab for KRASG12C CRC
Dr. Scott Kopetz discussed the KRYSTAL-1 study at AACR, presenting promising results of combining adagrasib and cetuximab to target KRASG12C mutated colorectal cancer, reporting a 34% response rate, with progression-free survival of 6.9 months and overall survival of 15.9 months in heavily pretreated patients.